| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2534772 | European Journal of Pharmacology | 2008 | 5 Pages |
Abstract
Since B cell activating factor belonging to tumor necrosis factor (TNF) family (BAFF) has been identified as a critical factor for B cell maturation and survival, convincing evidence indicates that deregulation of BAFF is involved in pathogenesis of B cell related autoimmune diseases. Blockade of BAFF activity significantly improves the symptoms of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis both in animal models and clinical trials. Therefore, BAFF-targeting therapy is a promising approach to treat B cell related autoimmune diseases.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Jian Sun, Zhou Lin, Jiannan Feng, Yan Li, Beifen Shen,